Fusion molecule based on novel taa variant
AssigneeThe Regents of the University of California
InventorsZhenhua Li, Arie Belldegrun
Life of this patent
Estimating the term…
Abstract
This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
Claims19
1-36. (canceled)
A method of treating an individual having a cancer characterized by an altered expression of a CAIX variant protein (CAIXv), said method comprising:
- (a) sensitizing antigen presenting cells in vitro with a sensitizing-effective amount of a chimeric fusion protein comprising the CAIX variant protein attached to a granulocyte macrophage colony stimulating factor (GM-CSF), wherein the CAIX variant protein comprises SEQ ID NO:
- 1 or a fragment of at least 20 contiguous amino acids of SEQ ID NO:1 that comprises G121 and S374;
- and
- (b) administering to an individual having said cancer or a metastasis thereof a therapeutically effective amount of the sensitized antigen presenting cells.
41-46. (canceled)
Dependencies are inferred from the claim text.